Chemistry:Benralizumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD125 |
| Clinical data | |
| Pronunciation | ben" ra liz' ue mab |
| Trade names | Fasenra |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618002 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6492H10060N1724O2028S42 |
| Molar mass | 146056.45 g·mol−1 |
  (what is this?) (verify) | |
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma.[3][4]
Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.[5][6] It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma.[7] It was granted designation as an orphan drug by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019.[8]
Common adverse effects include injection site reactions, which were reported in 2.2% of patients (vs. 1.9% for placebo) in clinical trials.[9]
References
- ↑ "Search Page - Drug and Health Product Register". 23 October 2014. https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00337.
- ↑ "Fasenra EPAR". 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra.
- ↑ Statement on a Nonproprietary Name adopted by the USAN Council: Benralizumab
- ↑ "Asthma & COPD--IQPC's Second Conference". IDrugs 13 (9): 601–4. September 2010. PMID 20799138.
- ↑ AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016
- ↑ "Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma". The New England Journal of Medicine 376 (25): 2448–2458. June 2017. doi:10.1056/NEJMoa1703501. PMID 28530840.
- ↑ "Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma". AstraZeneca. 2017-11-14. https://www.astrazeneca-us.com/media/press-releases/2017/fasenra-benralizumab-receives-us-fda-approval-for-severe-eosinophilic-asthma-11142017.html#!.
- ↑ "Fasenra granted US Orphan Drug Designation for eosinophilic oesophagitis" (in en). https://www.astrazeneca.com/media-centre/press-releases/2019/fasenra-granted-us-orphan-drug-designation-for-eosinophilic-oesophagitis-28082019.html.
- ↑ FDA Professional Drug Information
External links
- "Benralizumab". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/benralizumab.
| Products | |
|---|---|
| Predecessors and acquired companies | |
| People | |
 |  |
